Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials-Reference-Cited by-同舟云学术

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials

Published:2020-04-15 Issue:3 Volume:26 Page:450-458
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Tosetto Alberto¹,Neff Anne²,Lentz Steven R.³^ORCID,Santagostino Elena⁴^ORCID,Nemes Laszlo⁵,Sathar Jameela⁶,Meijer Karina⁷,Chowdary Pratima⁸^ORCID,Shen Chunduo⁹,Landorph Andrea⁹,Hampton Kingsley¹⁰^ORCID

Affiliation:

1. Hematology Department Haemophilia and Thrombosis Center San Bortolo Hospital Vicenza Italy

2. Department of Hematology/Oncology Cleveland Clinic Cleveland OH USA

3. Division of Hematology, Oncology, and Blood & Marrow Transplantation Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA USA

4. Fondazione IRCCS Cà Granda ‐ Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Haemophilia and Thrombosis Center Milan Italy

5. National Haemophilia Centre and Haemostasis Department Medical Centre of Hungarian Defence Forces Budapest Hungary

6. Department of Haematology Ampang Hospital Selangor Malaysia

7. Department of Haematology University Medical Centre Groningen University of Groningen Groningen The Netherlands

8. Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK

9. Novo Nordisk A/S Bagsværd Denmark

10. Department of Cardiovascular Science University of Sheffield Sheffield UK

Funder

Novo Nordisk A/S

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13980

Reference27 articles.

1. Surgery in patients with inherited bleeding disorders

2. Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery

3. ArmstrongE AstermarkJ BaghaeiF et al.Nordic hemophilia guidelines.http://nordhemophilia.org/library/Files/PDF‐skjol/NordicGuidelinesCongenitalHaemophilia_2017.pdf. Accessed November 7 2018.

4. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH

5. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life;Bleeding, Thrombosis and Vascular Biology;2024-04-22

2. Hemostatic cover in orthopedic surgery;Blood Coagulation & Fibrinolysis;2023-06

3. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care;European Journal of Anaesthesiology;2023-04

4. Surgical Procedures Requiring Hospitalization and Perioperative Management for Patients with Hereditary Bleeding Disorders;Clinical Pediatric Hematology-Oncology;2022-10-31

5. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies;Research and Practice in Thrombosis and Haemostasis;2022-07